IFN--y and/or TNF-o., three inducible subunits 131 i (low molecular mass polypeptide 2 [LMP2]), 132i (multicatalytic endopeptidase complex-like-I [MECL-l]), and 135i (low molecular mass polypeptide 7 [LMP7]) are expressed and incorporated instead of their constitutive counterparts into newly assembled proteasomes, which then are called immunoproteasomes (3) (4) (5) .
All proteolyticall y active l3-subunits are expressed as inactive precursors bearing N-terminal prosequences, which participate in cooperative proteasome assembly and prevent premature activation. The prosequences are autocatalytically cleaved off during the last step of proteasome assembly rendering the proteasome fully active (6) (7) (8) . The main function of immunoproteasomes is to produce peptides with basic and hydrophobic C-terminal residues that are better suited as ligands for MHC class I binding. Tmmunoproteasomes shape the immunodominance of the responding T cell pool by governing the generation as well as the destruction of T cell epitopes (9) .
In the human brain, proteasomes are expressed in the cytoplasm, the nuclei , dendrites, axons, and synaptic boutons of a series of different cell s including glial cells, pyramidal cells, Purkinje cells, and granular cells in the hippocampus (10, I I). Elevated proteasome activity has been observed after neuronal differenti ation, whereas decreased activity and expression are often associated with neurodegenerative di sorders and with age leading to protein aggregation, protein oxidation, and age-associated neurodegeneration ( 12) . The expression of immunoproteasome subunits is low in the human brain, and they have been localized in areas such as hippocampus and cerebellum (13) . Upregulation of immunoproteasome expression is associ ated with neuronal differentiation and has been observed during age-progression and neuronal di sorders such as Huntington's disease and Alzheimer's disease (10, 14) . In primary mouse microglia cultures, the expression of immunoproteasome subunits could be induced upon stimulation with IFN--y (15) . Other than these in vitro data, little is known about the in vivo expression of immunoproteasome in the murine brain under normal and inflammatory conditions.
In this study, we analyzed the formation of immunoproteasome in the murine brain after lymphocytic choriomeningitis virus (LCMV) in fection. Compared with that in other organs, the gross immunoproteasome induction in the brain is very low even after intracranial infection. Whereas microgli a readily expressed mature immunoproteasome, no immunoproteasome formation could be detected in neurons and oligodendrocytes. In astrocytes, immunoproteaso me expression was low and confined to the nucl eus. An accumulation of unprocessed immunoproteasomal precursors in primary astrocytes in vitro may correspond with the observed accumulation of immunoproteasomal precursors in LCMV-infected mouse brain in vivo. The apparent attenuation of immunoproteasome formation may contribute to the immune privilege of the CNS. 
Materials and Methods

Animals
Antibodies
The monoclonal mouse Ab Ct-p27 , clone IB5 , recognizes the Ct I-subunit iota of the proteasome and was obtained from Prof. Dr. KJaus Scherrer (Institut Jacques Monod, Paris, France). Polyclonal rabbit antisera were raised against epitopes of MECL-I (J32i) and LMP2 (131 i) , which are accessible on the outer surface of the immunoproteasome (B . Guillaume, J. Chapiro, V. Stroobant, D. Colau, B. Van Holle, G. Parvizi, M.P. Bousquet-Dubouch, I. Theate, N. Parmentier, and BJ. Van den Eynde, submitted for publication). They were affi nity purified and used in a I: I 0000 dilution for Western blot analysis or in a I :2000 dilution for immunohistochemistry. Polyclonal Ab recognizing LMP7 was a rabbit antiserum raised against the keyhole limpet hemocyanin-coupled peptide SDVSDLLYKYGEAAL of mouse LMP7 (mLMP7) (19 
Purification of 20S proteasomes, proteasome activity assays, non equilibrium pH gradient electrophoresis/SDS-PAGE, and Western blotting
The purification and acti vity assay of20S proteasomes, none quilibrium pH gradi ent electrophoresis (NEPHGE)/SDS -PAGE, and Western blot analysis was exactly performed as previously described (19) .
Sucrose gradient density centrifugation
One hundred milligrams of liver or brain tissue were lysed in buffer II (0.1 M KCI ,5 mM MgCI 2 , \0 mM HEPES, pH 7.2, 0.1 % Triton X-lOO) using a Dounce homogenizer. After son ification (5 cycles of 20 s; 60% intensity), the homogenate was centrifuged at 20,000 X g fo r 30 min at 4°C. The supernatant was loaded onto a gradient of 15-40% sucrose in 0.1 M KCI buffer and centrifuged at 40,000 rpm for 16 h at 4°C in a Beckman-Coulter (Krefeld, Germany) SW40Ti rotor. Afterward, fractions of 600 fl.1 were drawn, and proteasome activity was determined . Two hundred fjfty microliters of each fraction were then precipitated according to Wessel and Fliigge (20) . After a drying period, pellets were dissolved in 2% SDS and separated by SDS-PAGE. Proteasomal subunits were detected by Western blot analysis.
Quantitative RT-PCR
RNA was prepared from brain and liver samples or T2 clones, respectively, using the NucleoSpin RNA II Kit (product No. 740955250; Machery-Nagel , DUren, Germany) according to the manufacturer's manual. For the synthesis of single-stranded cDNA from pure total RNA, the ReverseTranscription System Kit (product No.A3500; Promega, Mannheim, Germany) was used. To determine relative gene expression, the LightCycier Fast Start DNA Master SYBR Green I Kit (product No. 12239264001 ; Roche, Grenzach-Wyhlen, Germany) was used in conjunction with the LightCycler Instrument (Roche) and the LightCycler Software Version 3.5 (Roche). Concerning the determination of relative IFN-')I expression, the TaqMan Master Kit (product No. 04535286001; Roche) was used in combination with an IFN-')I-spec ific probe (product No . 0468694200 I; Roche) . Sense and anti sense primers used for the PCR amplification were as follows: mouse (m)IFN-y 5' -ATC TGG AGG AAC TGG CAA AA-3' and 5'-TIC AAG ACT TCA AAG AGT CTG AGG-3' (annealing temperature = 60°C); mHPRT: 5' -TGG ACA GGA CTG AAA GAC TIG-3' and 5' -CCA GCA GGT CAG CAA AGA ACT TA-3' (annealing temperature = 59°C): mMECL-1: 5' -CGT CTG CCC TIT ACT GC-3' and 5' -CCA crr CAT TCC ACC TCC-3 ' (annealin g temperature = 62°C); mLMP2: 5'-TCC ACA CCG GGA CAA CC-3' and 5' -CCA GCC AGC TAC TAT GAG ATG C-3' (annealing temperature = 62°C); mLMP7: 5'-CTC CGT GTC TGC AGC ATC C-3' and 5' -TCC ACT TIC ACC CAA CCG TC-3' (annealing temperature = 60°C). The runs were programmed as fo llows: denaturation for 10 min at 95°C, amplification (35 cycles [40 cycles for mHPRT) with reading of the fluorescence at the end of each cycl e) for lO s at 95°C, 30 s at annea ling temperature, 20 s at n oc; and analysis of the products (reading of the fluorescence in a continuous mode) for 0 s at 95 T, 62°C to 9YC transition with 0. 1 °C increment/second . Fur the detection of IFN-')I expression, we used the TaqMan Master Kit (product No. 0453528600 I; Roche) in com bination with an IFN -')I-spec ific probe (product No. 0468694200 I; Roche). This run was programmed as follow s: denaturation for 10 min at 95°C and amplification (48 cycles with reading of the fluorescence at the end of each cycle) for lO s at 9YC, 30 s at ann ealing temperature, and I s at nT. The spec ificity of the amplificat ion was verifi ed by melting curve analysis (95°C for 0 s; 65°C for 15 s, 95° for 0 s with a temperature transiti on rate of 0.1 °C/s in a continuous acqui sition mode) or in case of IFN-')I by gel analysis of the amplified product. Relative gene expression was normalized to mHPRT mRNA content and evaluated according tu the Pfaffl method using the Excel-based su ftware tool REST (21 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) were mounted on Superfrost plus slides (Therm o Scientific), air dri ed, and circled with a liquid blocker. For the VL4 staining, sections were fixed for 10 min in 4% PFA, incubated in 50 mM NH 4 CI/PBS for 15 min , and further permeabilized with 0.1 % NP-401 PBS for 30 min. After blocking in 0.2% BSAIPBS for I h at room temperature, sections were incubated overnight at 4' C with the supernatant of a VL4 hybridoma followed by staining with a secondary anti-rat-cy3 IgG ( I: I (00) diluted in PBS . For CD3 staining, sec ti ons were fi xed for IS min in cold 100% ethanol , air dried, and further washed twice for 5 min in PBS supplemented with O. I % Tween 20 (Sigma-Aldrich) . For Ag retrieval, sections were furth er boiled in 0.2% citric acid (pH 6) for 30 min in a microwave oven and kept at room temperature for a further 30 min . Sections were subsequently washed twice in PBS and circled with a liquid bl ocker. Un specific binding was bl oc ked by in cubation in PBS/O. I % Tween 2011 % BSA for 10 min . Detection of infiltrating T cell s was perform ed by incubation of the sections with the primary Ab rat anti-human C D3 (diluted I :200 in PBSIO . I % Tweenl l % BSA) at 4' C overni ght. Visualization was performed using a secondary cy3-coupled anti-rat IgG (I: 1000). After washing, slides were always mounted in Moviol (Calbiochem, Bad Soden, Germany) and analyzed with a Zeiss Axioplan (Gottingen, Germany) microscope using the AxioVision Rei 4.6 and the ImageJ software.
Isolation ofCDllb+ cells
For the isolation of CD I I b+ cells, single-cell suspensions were generated according to the manufacturer's instructions from whole BALB/c brains using a commercially availabl e neuronal dissociation kit (product No . 13009323 1; Miltenyi , Bergisch Gladbach, Germany). CD II b+ cell s were isolated out of these suspensions by the MACS technology according to the manufacturer' s instructions using IS ILl CDllb microbeads (product No. 130049601 ; Miltenyi) per brain. To increase the purity, eluted cells were administered to a second column and th e purification procedure repeated. Purity of the isolated CD II b+ and CD II b-(flow-through) fractions was subsequently checked by lIow cytometry and reached a purity of 75-90%. An aliquot of 50 ILl of each fra ction was in cubated for 20 min at 4' C with an FITC-conjugated mouse anti-CD II b IgG (dilution I: 150 in FACS buffe r [PBS supplemented with 2 mM EDTA, 2% FCS , 2 mM sodium ac id] ; product No. MCA74 FA; AbO Serotec). After two washing steps in ISO ILl FACS buffer, cells were dissolved in 200 ILl FACS buffer and analyzed by flow cytometry using a FACScan fl ow cytometer (BD , Heidelberg, Germany) and the FloJo software (Tree Star, Olten, Switzerland) . Isolated fractions were subsequently used for western blot analysis.
Preparalion of primaly aslrocyles and aSlrocyle cell lin.es
Primary cortical astrocytes were prepared from 1-to 2-d-old BALB/c mi ce according to Falsig et al. (22) . Immortali zed astrocytes were ori ginally generated in the laborat ory of Klaus Pfizenmuier (IZI. Uni versity of Stuttgart, Germany) based on a protocol by Frisa et al. (23 ) . Cells were either left untreated or stimulated for 72 h in the presence of20 ng/mIIFN-' Y and further used for Western blot analysis.
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Disease score C57BU6 and LMPT'-mice were intracranially infected with 30 PFU LCMV-WE. From day 5 to day 7 postinfection , the degree o f disease was regularly scored in a blinded manner according to Langford et al. (24) with min or modifications. The evaluated categories I) orbital ti ghtening, 2) nose bulge, 3) ear position, 4) hunchback, and 5) locomotion constraint were separately graded as follow s: 0, not present; I, moderate; and 2, severe. The sum of the scores for each of the five categories yi e lded the fin al disease score.
Results
Extensive replacemenl of constilutive proteasomes by immunoproteasomes in most OIgans after LCMV infection
After a viral infection, IFN-' Y is released by T cells and NK cells and leads to the induction of immunoproteasomes. To investigate the extent of immunoproteasome induction, the subunit composition of proteasomes was analyzed in different organs from noninfected and virus-infected BALB/c mice by two-dimensional gel electrophoresis. Mice were infected with LCMV-WE i.v., and 8 d later, 20S proteasomes were isolated from liver, heart, lung, kidney, colon, intestine, and spleen and analyzed by NEPHGEI SDS-PAGE. In an uninfected state, all nonimmunological organ s mainly contained constitutive proteasome indicated by the predominant presence of the constitutive subunits B (~I) and MB I ( [35) . Also, marginal amounts of the corresponding immunoprotea some subunits LMP2 ([31 i) and LMP7 ([35i) could be observed under noninflammatory conditions in these organs. A higher basal immunoproteasome expression was observed in spleen, lung, colon, and intestine. After infection with LCMV, LMP2 and LMP7 were strongly upregulated, whereas their constitutive counterparts Band MB I had either di sappeared completely or were significantly decreased (Fig. I) .
Very low expression of immun oproteasome in the brains of LCMV-infected mice
Next we analyzed the proteasome subunit composition of the brain. To sel an acute infection in the brain, BALB/c mice were intracranially infected with 30 PFU LCMV-WE. In contrast with an i. v. infection, an intracranial infection with LCMV avoids a preteI'm clearance of the virus in the periphery and guarantees a local infl amm ati on of the brain , whi ch leads to a leth al choIiomeningitis on day 7 postinfection . At th e first si gns of di sease, mi ce were ellthanized, and proteasomes were isolated from the brain a nd analyzed by two-dimensional gel electrophoresis ( Fig. 2A ). In contrast with other organs (Fig. I) , there was no expression of immunoproteasomes in the brain of uninfected mice or after i.v. infection with LCMV-WE. Intracranial infection with LCMV merely resulted in a slight induction of LMP2 and LMP7 on day 7 postinfection.
To exclude that the low degree of immunoproteasome form ation is a consequence of the dramatic course of disease and based on the short time period available for tran scription, tran slation, and/or assembly of newly synthesized proteasomes, we changed our infection protocol to allow a more moderate course of meningitis resulting in survival and eventual recovery of the mice . To thi s end, mice were coinfected with 10 5 PFU LCMV-WE i.p. and 30 PFU LCMV-WE intracranially. This protocol leads to more rapid T cell primin g and inducti on of an LCMV-specific CTL response in the periphery, which reduces the viral load and results in a dimini shed CTL-mediated immunopathology (25) . After coinfection, the mice showed typi cal symptoms of on go in g inflammation like bri stled fur and an apathetic behavior, but, compared with mice that were only infected intracranially, they showed a moderate course of di sease and survived day 7, sometimes recovering completely. The coinfection protocol failed to induce substantial levels of immunoproteasomes up to day 10 postinfection when compared with other organs ( Fig. I ; for a densitometric analysis of LMP2, S, LMP7, and MB I spots in liver and brain, see Fig. 28 ). We conclude that the failure to detect immunoproteasome formation in the brain cannot be attributed to an early death after intracranial LCMV infection.
mRNA expression of IFN-y and immunoproteasome subunits in livers and brains of LCMV-infected mice
To investigate the molecular basis of attenuated immunoproteasome formation in the brain, we ana lyzed the mRNA expression of IFN--y and immunoproteasome subunits by real-time reverse transcription-PCR. Mice were infected either with 200 PFU LCMV-WE i.v., with 30 PFU intracranially, or simultaneously with 10 5 PFU i.p. and 30 PFU intracranially. Either on day 7
(single i.v. or i.p. infection) or on day 10 postinfection (combined i. v. and i.p. infection), RNA was isolated from liver and brain, and the mRNA expression for IFN--y, MECL-l , LMP2, and LMP7 was quant ified. After i.v. infec tion, we observed an up to 60-fold induction of IFN--y in the liver on day 6 postinfection, which decreased quite rapidly to a less than 20-fold induction on day 8 (Fig. 3A) . Immunoproteasome subunits were upregulated by 4-to 10-fold on day 4. This level remained stable until day 6 and then - •
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decreased to a lower magnitude on day 8 . Surprisingly, thi s induction had occurred on day 4, when there was still no IFN--y expression detectable. Probably, this can be attributed to other pro in flammatory cytokines, suc h as TNF-a and type I IFNs (IFNa , IFN-(3), which are known to induce immunoproteasome expression as well (26) . Intracranial infection as well as the coinfection protocol yielded a similar kinetic in the liver, althoughexcept for IFN--y and MECL-I in the coinfection model-the relative induction was significantly decreased compared with that for i.v. infection. Intravenous LCMV infection failed to ind uce high mRNA levels for IFN--y and the immunoproteasome subunits in the brain probably because the virus was cleared before it could cause a meningitis (Fig. 38) . In contrast, after coinfection and intracranial infection, we saw a fulminant 200-to 400-fold upregu lation of IFN--y mRNA in the brain, probably due to the infi ltration of mononuc lear cell s (27) . Whereas IFN--y expression after intracranial infection was strongly induced on day 6 and further increased unti l day 7, upregulation of this cytokine in coi nfected mice peaked on day 6 and declined thereafter. For the mRNA expression of immunoproteasome subunits in the brain of intracraniall y infected mice, we observed a steady increase up to day 7 with an up to 6-fold induction for MECL-I, up to 120-fold induction for LMP2, and up to 8-fo ld induction for LMP7. The relatively stronger induction of LMP2 compared with that of LMP7 and MECL-J was probably due to extremely low LMP2 expression levels in the uninfected brain_ Also, the coinfection protocol resulted in a substantial mRNA induction for MECL-I, LMP2, and LMP7 throughout day 4 to day 10 after which mi ce were sacrificed for the ana lysis of proteasome subunit composition (Fig. 2) .
Taken together, these data indicate that after intracranial infection with LCMV, the low level of immunoproteasome cannot be attributed to a lack of time for the induction of immunoproteasome. Even in the coinfection model, only minimal immunoproteasome formation could be detected on two-dimensional gels , whereas the same period of immunoproteasome synthesis in the liver of i.v. -infected mice led to an extensive replacement of constitutive proteasomes by immunoproteasomes (Fig. 2B) (19) .
Expression of immunoproteasome subunits in livers and brains of LCMV-infected mice on protein level
After induction by IFN-'Y, the immunoproteasome subun its MECL-I, LMP2, and LMP7 are synthesized as N-terminal extended precursor subunits, which then are autocatalytically processed during the assembly of the immunoproteasome (6, 7) . To investigate further the poor immunoproteasome formation in the brain, the expression of its subuni ts was analyzed on the protein level by Western blot analysis. Mice were infected either with 200 PFU i.v. or with 30 PFU intracranially. On day 8 postinfection, organs were recovered and analyzed by Western blot using Abs specific for MECL-I, LMP2, and LMP7 (Fig. 4) . Positive co ntrols were 20S immunoproteasomes purified from the liver of LCMVinfected mice. As a control for eq ual pro tea some loading, we monitored the a-type subunit iota (a I), which is part of both the constitutive proteasome and the immunoproteasome. Mature MECL-I with a molecular mass of 25 kDa could be observed in liver and brain of wild-type mice. No MECL-I was detected in LMP7 and MECL-I double knockout mice (L7M) as well as in LMP2 knockout mice due to the requiremenl of LMP2 for the incorporation of MECL-I (28). Mature LMP2 with a molecular mass of 2 1 kDa and mature LMP7 (23 kDa) were expressed in all samples except for the ones from the corresponding knockout mice. In the LMP2 blot, an additional band of ~23 kDa appeared in brain samples of intracranially LCMV-infected BALB/c mice. Such a band was also prominent in the liver sample of the L7M double knockout mouse, which is expected to represent the LMP2 precursor as it accumulated in the absence ofLMP7 and was absent in LMPT 1 -mice (8). It appears that the reduced immunoproteasome formation in the brain of LCMV-infected BALB/c might be due to an assemb ly defect.
Accum.ulation of immunoproteasome precursors in the brains of LCMV-infected BALB/C mice
To investigate further whether LMP2 precursors accum ul ate in brain, we performed sucrose gradient centrifugation. BALB/c mice as well as MECL-I -1 -ILMP2-1 -double knockout mice were infected i.v. or intracrania lly with LCMV-WE_ On day 8 and day 7 postin fection, liver and brain Iysates, respectively, were recovered and total Iysates subjected to density gradient centrifugation, and fract ions were analyzed by Western blotting . In the liver of LCMV-infected mice (Fig. 5A) , mature immunoproteasomes containing processed MECL-I (25 kDa), LMP2 (2 1 kDa), and LMP7 (23 kDa) were found in the fractions 9-14. In the brain samples LMP7 (135 i), and MB I (135) were assessed in the two-dimensional gels shown in Fig. I (li ver) and this figure (brain), and the results (in a. u.) were charted as shown. a.u ., arbitrary units. complexes, A similar accumulation of LMP2 and MECL-I precursors was not found in the livers of LCMV-infected mice even upon overexposure (Fig, 5A and data not show n) consistent with a rapid conversion of precursor complexes into mature proteasomes. Taken together, these data suggest that an impaired proteasome assembly contributes to the observed incomplete replacement of constitutive proteasome by immunoproteasome in the brain,
Localization of LMP2 and MECL-I in the brains of intracranially LCMV-infected 8AL8/C mice
To gain further insight into immunoproteasome expression in the brain after LCMV infection, we pursued a histologic approach and analyzed brain inf1ammation by immunof1uorescence microscopy. Sections from the brain of LCMV-infected BALB/c mi ce and naive control mice were stained with DAPI and the LCMV nucleoprotein-specific mAb VL4. In accordance with a previous study (29) , viral in fection was prominent in the meninges, the ependymal cell s of the ventricles, and the choroid plexus as well as in the regions around the ventricles on day 7 after intracranial LCMV infection (data not shown). Because LCMV is a noncytopathi c virus, the damage induced in the CNS is not caused by th e virus, but is rather a result of the subsequent immune response and caused by infiltrating T cell s. Whereas we observed no T cell infiltration in the brain of naive control mice, T cell infiltration in the infected brains strongly correlated with the sites of LCMV infection (data not shown).
To identi fy cell types with in the brain by immunof1uorescence histology that express immunoproteasome and may accoun t for the accum ul ation of immunoproteasomal precursors, we used newly generated polyclonal Abs specifi c for M ECL-I and LMP2, whi ch bind to epitopes predicted to li e on the outer surface of immunoproteasomes (B . Gui ll aume et aI., submitted for publication). The specificity of these Abs was verified extensively in intracra ni ally LCMV-in fected wild-type and MECL-I -1-ILMP2 -1 -double-knockout mice (S upplemental Figs. 1,2) ; stainings with the second-stage reagents alone also showed no fluoresce nce above background (data not shown). The highest LMP2 and MECL-I fluorescence was detected in the meninges, the outer brain parenchyma, the ventricular ependymal cells, and the regions around the ventricles . At a higher magnification, LMP2+ cells in the ventricular region revealed a ramified morphology suggesting microglia as potential producers of immunoproteasome.
Colocalization of LMP2IMECL-1 and {ba -1 in the brains of LCMV-infected mice
Next we investigated a possible localization of immunoproteasomes in microglia after intracranial LCMV infection . As a marker for microglia we used Iba-l , also named allograft inflammatory factor-I (AIF-l). Iba-I is exclusively expressed in cells of the monocytic lineage and is associated with microglial activation in the brain (30) . Its constitutive expression prevails in CNSassociated macrophages in the perivascular space and the meninges as well as in microglia within the brain parenchyma. Most prominent signals for Iba-J were observed in the region of the meningeal and ventricular regions with most prominent staining in the region around the 4th ventricle. Comparing naive mice with intracranially LCMV-infected mice, we observed a significant increase in the number of microglia and intensity of Iba-I staining within these regions of infected mice (data not shown) . intracranially. On day 7 postinfection, brains were recovered, and coronal cryosections of the diencephalon were costained for Iba-I and LMP2 or MECL-l, respectively. As expected, MECL-I -
To investigate if microglia express immunoproteasomes in the LCMV-infected brain, wild-type mice as well as MECL-I -
LMP2 -1-double -deficient mice showed no signal for both immunoproteasome subunits indicating the specificity of the immunoproteasome staining (Fig. 6A, 6B ). Concerning the expression of LMP2 and MECL-l in wild-type mice, we observed a partial colocalization with Iba-l, which was most prominent in the outer regions of the cerebral cortex in close proximity to the meninges, which persisted beyond day 10 postinfection (data not shown). Second-stage controls and compensation controls confinned the specificity of stainings for LMP2, MECL-I, and Iba-I (data not shown). We conclude that Iba-I + cells are the main producers of immunoproteasome after intracranial LCMV infection. Although perivascular as well as meningeal macrophages and monocytes are also known to express Iba-I, the Iba-I +LMP2+ cells as well as the Iba-I +MECL-I + cells can be assigned to be microglia due to their characteristic morphology. However, in addition, we also saw some immunoproteasome-positive cells that were Iba-J negative.
After intracranial LCMV infection, immunoproteasome can be detected exclusively in the nuclei of astrocytes
Astrocytes represent the main glial cell type within the brain. They are involved in many processes related to CNS homeostasis including the release of neurotrophic factors and the guidance of neuronal development, the regulation of extracellular pH and K+ levels, and the formation and maintenance of the blood-brain barrier. After activation, astrocytes proliferate and enhance the expression of GFAP in a process termed astrogliosis, which represents a common feature of many neurodegenerative diseases (31) . A comparison of naive versus LCMV-infected brain sections showed a slight increase in the number of stained astrocytes that was most obvious in the region of the 4th ventricle and the hippocampus (data not shown). We performed costainings for GFAP and LMP2 or MECL-I, respectively, of brain sections of BALB/c mice, which were intracranially infected with 30 PFU LCMV-WE alone or coinfected with 30 PFU intracranially and 10 5 PFU i.p.
Second-stage and compensation controls confirmed th e specificity of the GFAP stainings (Supplemental Fig. 3B, 3C ). In contrast with microglia, we could not observe any colocalization of GFAP and immunoproteasome in the cytosol of astrocytes either on day 7 postinfection or on day 10 postinfection (Supplemental Fig. 3A) . However, images of GFAP+ astrocytes of hi gher magnification revealed LMP2 staining in astrocytes that did not colocalize with th e intermediate filam ent GFAP in the cytosol but rather colocalized with DAPI in nuclei of GFAP+ astrocytes (Fig. 7) . MECL-I also colocalized with DAPI in nuclei of GFAP+ astrocytes (Supplemental Fig. 4 ), suggesting that astrocytes accumulate immunoproteasome in the nucleus.
Immunoproteasome cannot be detected in neurons and oligodendrocytes of LCMV-infected mouse brain
We also analyzed the capacity of neurons and oligodendrocytes to express immunoproteasome. As a marker for neurons, we used a mouse Ab that recognizes a neuron-specific nuclear protein called NeuN. Oligodendrocytes were detected using an Ab specific for 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase), which is a marker for oligodendrocytes and Schwann cells. Bleed-through and second-stage controls showed no unspec ifi c staining for both cell types (Supplemental Fig. 5C ). The analysis of the coexpression of LMP2 and NeuN revealed that the majority of neurons did not express immunoproteasome (Supplemental Fig. 5A ), although a few neuronal nuclei in areas of strong immunoproteasome expression appeared to be slightly positive for LMP2. In costainings of LMP2 and CNPase, we failed to detect any colocalization indicating that oligodendrocytes do not express immunoproteasomes (Supplemental Fig. 5B ) .
Immunopl'Oteasome expression in isolated microglial cell populations
To corroborate further our immunohistochemical data testifying to immunoproteasome formation in microglia, we determined the immunoproteasome expression in CDllb+ cells magnetically sorted from single-cell suspensions of intracranially LCMV-infected brains by Western blot analysis (Fig. 8 ). The quality of the isolation was analyzed by flow cytometric analysis and revealed purities of the isolated CD II b+ cells between 75 and 90% (data not shown). The immunoproteasome subunits LMP2 and LMP7 were exclusively found in isolated CD II b+ cells, whereas expression of the a-subunit iota, which is present in constitutive and immunoproteasome, could also be detected in the flowthrough fraction indicating the expression of constitutive proteasome in other cell types of the brain. DAP! + LMP2 + GFAP. The magnifications of shown images range from X 100 to X400. The experime nts were performed three times with si milar outcomes.
mai n cell types expressing immunoproteasome in the brain after intracranial LCMV infection. Although immunoproteasome sta ining was observed in nucl ei of astrocytes by immunohi stology (Fig. 7 , Suppleme nta l Fig. 4) , accord ing to Western ana lysis (Fig. 8) , CD II b-cell s do not seem 10 co nlribute sig nifi cantl y to the total pool of immunoproteasome in the brain.
lmmunoproteasome expression in astrocytes after in vitro stimulation with IFN-y
To investigate further the immunoproteasome expression in astrocytes under inflammatory co nditi ons, we decided to stimul ate primary astrocytes with IFN-'Y in vitro. Primary astrocytes, which were prepared from the corti ces of neonatal BALB/c mice, were cultured for 3 wk and subseq ue ntly either left untreated or stimulated with 20 ng/ml IFN-' Y fo r 72 h. Afterward, the immunoproteasome expression was analyzed in total Iysates by Western
Immunoproteasome expression in isolated microglia. T hree BALB/c mice were intracranially in fected with 30 PFU LCMV-WE. On day 7 postin fection, single-cell suspensions were generated from the brains and CD II b+ cells isolated by magnetic sorting . After the purity of the isolated fract ions has been confirmed by flow cytometry, total Iysates of the fractions were analyzed for their immunoproteasome content by Western blot using Abs speci fi c for LMP2, LMP7, and the constitutive a-type proteasome subuni t iota (a l ). As a pos itive cont rol (+) , p urified irnrnunoproteasorne from LCMV-infected mouse liver was used. The experiment was reproduced two times.
blot for LMP2, LMP7, and MECL-I. As show n in Fig. 9 , primary astrocytes expressed matured LMP2 and LMP7 exclusively after stimulation with IFN-'Y. Notably, the protein band detected in astrocytes wi lh the MECL-I -specific Ab showed a molecular mass of ~30 kDa , which was significantly hi gher than that of (8) immortalized astrocytes were analyzed by Western blot for the expression of MECL-l , LMP2, LMP7 , and Iota. As a pos itive control. C, purified immunoprot easo me from LC MV-infected mouse li ver was used. The experiments were performed twice a nd yielded similar results.
mature MECL-I in hi ghly purified mouse 20S immunoproteaso mes with a size of 25 kDa, suggesting that primary astrocytes contain the MECL-I precursor but not the mature subunit. We also analyzed the immunoproteasome expression in an immortalized astrocytic cell line. In immortalized astrocytes, we observed expression of mature LMP7 and LMP2 in the presence and absence of TFN--y but also detected an accumulation of LMP2 (23 kDa) and MECL-I (30 kDa) precursors after IFN--y stimulation (Fig. 98) .
The immortalized astrocyte line showed low immunoproteasome expression of both mature and immature subunits already in unstimul ated cells, suggesting that they had partially lost their inducibility. These data suggest that the observed accumu lation of unprocessed, immunoproteasome precursors in the brain of intracranially LCMV-infected mice occurs in astrocytes, whereas microglia and monocytes, which represent the main producers of immunoproteasome, contain mainly mature immunoproteasome.
Immunoproteasomes contribute 10 the severity of LCMV-induced meningitis
Recently, a new function of immunoproteasomes in governing the production of proinflammatory cytokines and differe ntiati on of Th 17 cell s has been described (I, 32). To assess whether immunoproteasomes may contribute to the immunopathological development of meningitis triggered by intracranial LCMV infection , we infected both C57BLl6 wild-type and LMPT 1 -mice with LCMV-WE intracranially and monitored the meningitis disease score over time (Fig. 10) . The onset of meningitis symptoms in LMPT 1 -mice was delayed by 20 h (164 h compared with 144 h postinfection in wild-type mice), and the severity of disease was lower in LMP7-deficient mice at all time points. Moreover, wildtype mice had to be euthanized 164 h postinfection because of severe sy mptoms of meningitis, whereas LMP7 -1 -mice survived about I d longer. Given that LMP7 activity is required for the normal production of proinflammatory cytokines (32) and th at microglia and macrophages, which produced these cytokines, are th e only cell types in the inflamed CNS that assemble considerable amounts of mature immunoproteasomes, we propose that LMP7 defi c iency might limit the inflammati on-promoting function of these professional APCs in the CNS .
Discussion
The antiviral immune response leads to the production of the proinflammatory cytokines TFN--y and TNF-Cl, which establish the inflammato ry environment. One effect of th ese cytokin es is a stron g transcriptional induction of the immunoproteasome subunits LMP2 (13 1 to the replacement of the constitutive subunits 8 (131), MC 14 (132) , and MB I (135) in the inflamed tissue. We analyzed the proteasome composition in different mouse organs after LCMV infection. We observed in most organs an extensive change from constitutively expressed proteasomes in a noninfected state toward immunoproteasomes in infected organs (Fig. I) . The brain, however, was different. Despite a cytokine-driven induction of immunoproteasome on the transcriptional level (Fig. 3) , thi s induction resulted in only margina l replacement of constitutive proteasomes by immunoproteasomes on day 7 postinfection (Fig. 2) .
The assembly of the (immuno-)proteasome during neosyn thesis is a multistep event, where N-terminal prosequences as we ll as carboxy-terminal extensions of the subunits actively participate in COHect assembly leading to the autocatalytic cleavage of Nterminal prosequences and functional activation (7) . While performing sucrose gradient centrifugation with brain Iysates from LCMV-infected mice, we found an accumulation of immunoproteasome precursors (Fig. 5 ) in 16S gradient fractions suggesting that the dimerization of two half-proteasomes and autocatalytic processing of immunoproteasome subunits seems to be impeded in the brain. Although the mature forms of LMP2 and MECL-I are predominant also in the LCMV-infected brain, the mere detection of LMP2 and MECL-I precursors indicates that immunoproteasome assembly is impeded (8) . The precursors are hardly detectable in Western analysis if immunoproteasomal precursor processing proceeds normally as precursor complexes are either rapidly matured or degraded if they fail to mature (33, 34) . Based on these data, we postulate the existence of a posttranslational mechanism that regulates immunoproteasome formation in cells of the CNS, where no-or low-immunoproteasome expression is desired despite ongoing IFN release. This hypothesis is attractive given that the brain is an immune-privileged organ , where uncontrolled inflammatory responses may cause destruction of essential and poorly regenerating cells. To prevent immunopathologic damage, the unique anatomy of the brain including the blood-brain barrier and the blood-CSF barrier as well as the absence of classic lymphatic vessels clearly provides the cells of the CNS with a protective status against overt immune attack. However, in addition to these anatomic features, immune tolerance in the brain is also actively maintained by molecular determinants one of which may be the reduced form ation of immunoproteasomes. The proteasome regulators PBI , PA200, PA28Cl, or the assembly factor UMP I, which all have been proposed to affect immunoproteaso me assembly, were not significantly different in their expression in the intracranially infected brain compared with i.v. infected liver (A. Dahler, unpubli shed observations) and thu s are not likely to play a role in the observed failure of proper immunoproteasome formation in the brain .
Despite major advances in proteasome research, the characterization of proteasome expression and activity in the CNS is sti ll rudimentary. To get a deeper insight into immunoproteasome expression in th e infl amed brain, we estab li shed an immunohi stoc hemi cal protocol for the detection of immunoproteaso meexpressing cells using Abs directed against peptide epitopes of mMECL-1 and mLMP2, which according to three-dimensional struc ture models shou ld be accessible from the outer surface of the assembled immunoproteasome. This was an important prereq ui site for thi s study as the 20S proteasome is very stable and not easily denatured by methods that shou ld preserve the cellular structures in brain slices. The Abs used turned out to be excellently suited for the histological detection of immunoproteasome in brain cryosections. Moreover, they were able to detect the respective precursors pre-MECL-I and pre-LMP2 in Western blots. We obta ined speci fi c stainings for th e respective subunits in brain cryosections of intracrani ally LCMV-infected mi ce that were absent in naive mice and in the respective LCMV-in fected knockout mi ce underlining the reli ability of the performed stainings (Supplemental Figs. I, 2). Such important negative controls have not been appli ed in earlier immunohi stochemical studies of immunoproteasome expression (3 5, 36) raising some doubts about the interpretation of these studies. Costainings with cell markers s pec ifi c fo r ne uro ns (Ne uN) and oli gode ndrocytes (CNPase) showed no to low colocalizatio n with the respective immunoproteasome subunits (Supplemental Fig. 5 ), indicating that these cell s do no not seem to express immunoproteasome in vivo. Using Jba-I as a marker specifi c for microg li a cells, in fi ltrating monocytes, and macrophages, we could identify these cell s as the main producers of imlllunoproteasome in th e infl amed murine brain with strong immunoproteasome expression in the cytosol and the nucl eus (Fig.  6 ) . This co nfirm s previ ous results by Stohwasser et al. ( 15) who could induce immunoproteasome expression in isolated microglia and the microgli a cell line BV-2 upon stimulatio n with IFN-' Y. Microgli a are generally considered to be immunologicall y quiescent under nonpathological conditions as indicated by their ramifi ed morphology, marginal expression of MHC cl ass I molecul es, and the complete absence of MHC class II surface expression. After activati on, however, they transform into highly active effec tor cell s as indicated by their contracted morphology and their proli ferati on. Due to an IFN-' Y-induced increase in MHC class I and MHC class n surface expression, as well as the upregulation of costimulatory molecul es such as B7 . 1 (CD80), B7 .2 (CD86), and ICAM-j , they are the most-effi cient APC population in the brain parenchyma (35, 37) . Our findin g that upon a viral infecti on these cell s adapt their proteasome composition to the requirements of an optimized MHC class I epitope processing by the expression of immunoproteasome strongly supports thi s hypothesis and suggests that in the context of viral infection, these cells participate in Ag presentation. In contrast, the Ag presentation capacity of astrocytes, the major gli al cell population, remains in question and is controversially discussed. Although increased astrocytic cell numbers are associated with many neurodegenerative di seases and could be shown to present mye lin basic protein to encephalolitogenic T cell s (38) , their presentation capacity remains a matter of de bate. Sedgwick and colleag ues (39) could show that astrocytes ca n acti vate T cell s onl y if these cell s were incubated in the presence of microgli a or IL-I , indicatin g that an additional APC is required.
In th is study, we hardly could observe any cytosolic expression of MECL-I or LMP2 in GFAP+ astrocytes (Supplemental Fig. 3) , indicatin g that these cell s do not seem to participate in the generati on of immunoproteasome-dependent epitopes. Based on our immunohi stochemi cal data, we the refo re pos tul ate th at in th e LCMV-infected brain, the fun ction of Ag processing and prese ntati on is mainly fuHill ed by mi crogli a, whi ch represe nt the most dominant immunoproteasome-e xpressing cell populatio n in the brain . An addition al role of CNS-associated DCs and Illacrophages was not analyzed but cannot be excluded and seems to be qui te li kely, whereas ne urons, oli godendrocytes, and astrocytes do not seem to be involved.
To investigate further the observed accumul ation of immunoproteasome prec ursors in the brain of LCMV-infected mi ce, we analyzed th e maturati on status of immunoproteasomes expressed by mi crogli a: CD I I b+ cell s were isolated fro m LCMV-in fected mouse brains, and total Iysates were analyzed by Western bl ot. Both LMP2 and LMP7 were mature and fully processed suggesting proteolyti c competence of immunoproteasomes in mi crogli a (Fig. 8) . In contrast, immunoproteasome expression was absent in the cytosol and instead MECL-I and LMP2 were detected 5559 in the nuclei of astrocytes (Fig. 7, Supplemental Fig. 4 ) . It remains to be investigated whether these nuclear immunoproteasomes are proteolyticall y active, mature immunoproteasomes or if they represent unprocessed, immature proteasome precursors th at are deposited in the nucle us in an inactive state. The exclusive detecti on of MECL-I precursors rather than mature MECL-I in total Iysates of IFN-' Y -stimul ated, primary astrocytes (Fig. 9 ) strongly suggest astrocytes as ca ndidate cell s accounting for the accumul ati on of immunoproteasomal precursors in brain and together with our in vivo hi stochemi cal data would be consistent with the involvement of the nuclear envelope in the compartmentali zation of partially assembled immunoproteasomes. E nenkel and colleagues (40, 41 ) showed that in yeast, 13S-16S proteasome precursor complexes described as half-proteasomes are transported via karyopherin into the nucleus, and they postul ated th at in yeast the final dim eri zati on ste p and the autocatalyt ic processing of f3-subunits takes place in the nucleus. In case thi s fi ndin g would be ex tend ed to hi gher e ukaryotes, th e nu c lear immunoproteasome staining in astrocy tes may be due to an attenuation of nuclear proteasome assembly in astrocytes. Moreover, one could specul ate on the presence of an additi onal factor fac il itating proper immunoproteasome maturation and translocation back into the cytosol that is mi ssing in activated astrocytes thu s causing the accumul ation of immunoproteasomes in the nucleus. To date, none of the described 20S proteasome assembly factors, the (X-ring chaperone PAC 1-4, and the f3-ring chaperone hUMPI show selectivity for immunoproteasomes compared with constitutive proteasomes. On the other hand , the multitude of recently di sco vered 26S proteasome chaperones should encourage the search for differently expressed immunoproteasome-selective assembly factors. It is quite striking that both in primary astrocytes and in one astrocytic cell line, IFN-' Y-inducible MECL-I precursors of 30 kDa accumul ate in the absence of mature MECL-I (25 kDa). Consistent with thi s accumulation, the LMP2 prec ursor (23 kDa) also accumulated in an immortalized astrocytic cell line upon IFN-' Y indu cti on, whi ch may refl ec t the parti al dependence of LMP2 processing on the presence of MECL-I in the compl ex (8, 16) . In primary astrocytes, no accumulation of LMP2 precursor was detected, but the quantity of mature LMP2 was very low compared with th at of mature LMP7 . LMP7 is known to incorporate into 20S proteasomes independentl y of LMP2 and MECL-I and may hence not be affected by the accumul ati on of MECL-I precursors.
Proteasome inhibition becomes an emerging strategy for the treatm ent of a vari ety of autoilllmune, neurodegenerative , and pro li ferati ve di sorders: bortezo mib, a proteasome-specifi c inhibi tor applied in the treatment of multiple myeloma, reduces cytokine prod ucti on upon infl ammati on. However, its therapeuti c suitabi lity is limited due to considerable toxicities, and its therapeuti c use in chroni c inflammati ons remains probl emati c. Recently, Muchamu el et al. (32) presented an immunoproteaso me-spec ific inhi bitor targeting the chymotrypsin -like activity of the LMP7 subunit. In animal models of autoimmune di sorders including di abetes and coll agen-induced arthritis, PR-957 treatment afforded an impressive attenuati on of di sease and a suppressio n of proinft amm atory cytokines (42) . This novel functio n of immunoproteasomes might al so ex plain why we could observe a protracted and less severe course of meningiti s in LMP7-1 -mi ce compared with that in C57BLl6 wild-type mice. Given that mi croglia-like cell s seem to be the only cell types in the CNS that produce substantial amounts of intact immunoproteasomes, we assum e that the lack of LMP7-dependent producti on of proinfl amm atory cytokines by these cell s most likely accounts for the ame lioration of LCMV-induced menin giti s, which constitutes a new phenotype of LMP7 -1 -mice.
Understanding the role of immunoproteasome expression as well as the role of its reduced formation in the brain could provide new insights into how an immune response is regulated in an immuneprivileged organ and how immune tolerance can be actively attained. Tmmunoproteasome-spec ifi c inhibitors like PR-95 7 will be instrumental in this respect and may represent a promising strategy for the treatment of chronic inflammation-associated neurologic disorders.
